The $63.5 million contract aims to support UH in developing analytical modeling and simulation platforms that help the U.S. Army make timely and effective decisions. Photo via uhsystem.edu

The University of Houston was recently awarded its largest grant in history—this time, from the U.S. Department of Defense.

The $63.5 million contract aims to support UH in developing analytical modeling and simulation platforms that help the U.S. Army make timely and effective decisions, according to a release from UH.

Craig Glennie, professor of civil and environmental engineering and director of engineering defense research initiatives at the UH Cullen College of Engineering, who is leading the project, says the team's work will focus on creating tools for the time period before conflict begins.

“We are not looking at what happens once bullets start flying. We are looking at what happens during the competition and crisis phases, the buildup and the posturing and the projection of forces before you actually get to the point of armed conflict,” he says in a statement. “The Army needs tools to understand how they can effectively position themselves and project their force towards the adversary in such a manner that they can avoid armed conflict, or if that is not possible, be prepared for the onset of armed conflict.”

The team, which also includes members from the University of Massachusetts Amherst, New Mexico State University and other organizations, will work closely with the U.S. Army Combat Capabilities Development Command Analysis Center, known as DAC. They've been commissioned to help build realistic modeling, analysis and simulation tools that the Army can use in the "future battlefield."

DAC has named several high priority issues for the team including quantum technology, artificial intelligence, and machine learning.

“For example, we will look at the electromagnetic spectrum, at owning the airspace, and projecting that we have the radio frequency technology that is capable of jamming a neighbor’s signals," Glennie adds.

UH president Renu Khator says the university is honored to revive the contract.

“We understand the significance of this project in enhancing the Army’s decision-making capabilities, and we are proud to contribute to our nation’s security and strategic competitiveness," she said in a statement. "We look forward to the remarkable contributions that will emerge from this collaboration, strengthening the University of Houston’s commitment to driving innovation that matters.”

UH has inked a number of grants and contracts in recent months that are pushing innovative initiatives forward at the university.

Last month, UH received a $100,000 grant from the Baker Hughes Foundation to go toward workforce development programs, and environmental justice research at its Energy Transition Institute. The ETI was launched last year through a $10 million grant from Shell USA Inc. and Shell Global Solutions (US) Inc.

And earlier this month, Houston-based The Welch Foundation awarded its inaugural $5 million Catalyst for Discovery Program Grant to a new initiative led by Jeffrey Rimer, UH's Abraham E. Dukler Professor of Chemical Engineering. The grant launched the Welch Center for Advanced Bioactive Materials Crystallization, which will build upon Rimer's work relating to the use of crystals to help treat malaria and kidney stones.

Craig Glennie, professor of civil and environmental engineering and director of engineering defense research initiatives at the UH Cullen College of Engineering, is leading the project. Photo via uh.edu

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.